iShares Nasdaq Biotechnology (IBB) -Nasdaq The best indicator for our biotech portfolios are biotechnology indices such as IBB, NBI, XBI or XLV. By looking at the IBB daily chart, we get the whole picture of the latest epic run in the biotech sector during 2013, with a whopping run from 134.21 to 227.06 points, gaining 69.2%, while […]
BMY – Quick Chart Update
Bristol-Myers Squibb Company (BMY) -NYSE Interesting price action since September 9th after breaking out the downtrend line around $41.90, we kept watching the chart day after day during the preparation to AASLD reaching the high of $47.90, followed by a price consolidation and forming a flag pattern that we discussed several times through the private […]
ONTX – Looking For The Reversal Pattern
Onconova Therapeutics, Inc. (ONTX) -Nasdaq Onconova has recently plunged about $19 from the 52-week high at $31.13, reached just a month ago to the current level in mid-$13s and reaching the low of $12.03 today. Surprising given the Phase 3 readout coming up and final results from the Phase-II trial of oral rigosertib in 1st-line Low-Risk […]
Merck – Quick Chart Review
Merck & Co. Inc. (MRK) -NYSE For the first time since March 1st, MRK’s price dropped below its 200-Day Moving Average. This is worth a deeper look at the price action and the indicators are showing a “Bullish Divergence” and within the oversold zone. Merck will take part at the (IASLC) the 15th World Conference on […]
ACHN – In Consolidation Mode
Achillion Pharmaceuticals, Inc. (ACHN – Nasdaq) On July 1, 2013 the FDA placed a clinical hold on Achillion’s hep C drug and the shares plunged 22% from $8.36 to $6.17 the next morning. Since then the shares have traded sideways in a horizontal channel between $6.12 to $7.32. In the second quarter earnings press release Achillion […]
PGNX – Preparing For The Next Run
Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq Since my latest “Chart & TA” report “PGNX – A Hidden Bullish Divergence” on Aug 22nd, 2013. PGNX has been trading up and gained 33% in just 9 trading days, breaking out several resistance lines as I predicted in the last TA report What’s Next The price at this level around the […]
AMRN – Another Breakout – Chart Update
Amarin Corporation plc (AMRN) -Nasdaq Since my latest “Chart & TA” report AMRN – Running Up To The AdCom on Aug 30th, 2013. AMRN kept trading up and gained 4.7% , reaching the downtrend line (brown color on the chart) around $6.65. There we witnessed a real control’s war between the bulls and the bears around 12:15 […]
RPTP – New All Time High
Raptor Pharmaceuticals Corp. (RPTP) -Nasdaq Opportunity knocks all the time, but you have to be ready for it. If the chance comes, you must be ready and quickly respond to take advantage of it. On Aug 29. 2013 Gravity Research initiate a bearish report “Initiating Coverage on Raptor Pharmaceutical Corporation (NASDAQ:RPTP) – Strong Sell” causing a […]
AMRN – Running Up To The AdCom
Amarin Corporation plc (AMRN) -Nasdaq The price closed above the 100-Day moving avarage and the $6.34 resistance line, while the indicators still positive and wants more upside. The next important line to breakout is the Brown downtrend line around $6.70 that will make the weekly resistance line at $7.56 as the next target. Expect some technical correction […]
PGNX – A Hidden Bullish Divergence
Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq On June 11, 2013 Progenics and Salix (partner) announced an FDA Advisory Committee (AdCom) is scheduled to review Relistor sNDA for opioid-induced constipation(OIC) in patients with chronic pain. On July 27, 2012 Salix (SLXP) and Progenics received CRL from the FDA regarding the RELISTOR sNDA. But Slaix filed a formal appeal […]
IBB – Technical Commentary
iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolio are the biotechnology indices IBB, NBI, XBI or XLV. After publishing “IBB – Biotechnology Index at All Times High“, we wanted to maintain our focus on the IBB. In today’s video “IBB – Market Activity” Tony noted a large bearish bet or hedge […]
ASTX – Breaking out of the Downtrend Channel
Astex Pharmaceuticals, Inc. (ASTX) -Nasdaq ASTX had an epic run that started at the end of February from the low of $2.94, just after two months of price consolidation, and reached a six year’s high of $6.95 on April 30, 2012. From that point, the stock started a deep technical correction, trading in a downtrend channel […]
BMY – In A Consolidation Mode
Bristol-Myers Squibb Company (NYSE: BMY) BMY had an amazing run ahead of ASCO-2013 that left many well-planned traders very happy. The stock found strong support near the 50-Day Moving Average around $39.50 where many traders(ourselves included) started initial positions. The stock had a great run into the ASCO abstracts release on May 15th, moving roughly […]
SRPT – Sarepta – Is It The Time For A New High?
Sarepta Therapeutics, Inc – Nasdaq(SRPT) Sarepta is one of the most followed tickers in twitterville with a real bulls/bears debate. It has strong moms’ advocacy groups fighting full strength to get the drug Eteplirsen an AA (Accelerated Approval) and as fast as they can to the market. For some kids, every day counts as they are […]
IBB – Biotechnology Index at All Times High
Nasdaq Biotechnology Index Fund ETF (IBB) The best indicator for our biotech portfolio are the biotechnology indexes like IBB, NBI, XBI or XLV. Since we already published “The IBB and SPX In The Decision Zone“, we will maintain our focus on the IBB. By looking at the IBB daily chart, we get the whole picture […]
DCTH – Soaring Ahead of The Upcoming Advisory Committee
Delcath Systems, Inc. (DCTH) -Nasdaq DCTH has been on our watch list for a while, looking for an entry point. we kept following out the stock performance at the forum and stated a position at $1.63 just after the price found a support around the 200-day Moving Average, also added more shares to the position at […]
XNPT – It’s Time to Join The Run To The Ph-3 Resutls
Xenoport, Inc. (XNPT) -Nasdaq Lately, the reals runner were those with pending clinical trial data, where we saw TSRX and ZIOP’s share price move much more than the PDUFA runners. After TSRX and ZIOP(data from both are expected this week), we want to have a look at XNPT, which is expected to release Phase 3 […]
SGMO – Is it The Time For a Correction
Sangamo Biosciences Inc. (SGMO) -Nasdaq Within three months the share price of SGMO doubled, soaring from the $5.50 area and reaching a new 5 years high of $11.24, getting a boost from the hype around the clinical data that investors were anticipating to be presented at CROI 2013. Jason had a thorough report “SGMO: Sangamo […]
DEPO – Action Ahead Of The AdCom
DepoMed Inc. (DEPO) -Nasdaq Serada is an investigational formulation of gabapentin, an FDA-approved immediate release pharmaceutical for the treatment of partial epilepsy and management of postherpetic neuralgia (PHN). Recently published studies suggest the potential application of gabapentin for the treatment of menopausal hot flashes. Based on these findings, Depomed has secured exclusive rights to develop […]
SRPT – Preparing For The Next Move
Sarepta Therapeutics, Inc. (SRPT)-Nasdaq Sarepta is a biotech company under the spotlights since early October 2012, after presenting strong Phase IIb results for the compound Eteplirsen in the treatment of Duchenne Muscular Dystrophy. On October 3rd, 2012, SRPT jumped an unbelievable 199.7% by the closing bell, but as with every huge spike, profit taking started […]
